Who We Are
Generation Bio is creating a breakthrough class of genetic medicines that deliver durable, high levels of gene expression and can be re-dosed to titrate and sustain effect. We were founded by Atlas Venture in 2016 based on the research of Rob Kotin, Ph.D, who as a Senior Investigator at the National Institutes of Health discovered a novel method for non-viral gene transfer, known as closed-ended DNA, or ceDNA.
Building on this foundation, we have created our GeneWave platform, the first therapeutic application for ceDNA. GeneWave uses a lipid nanoparticle to deliver ceDNA to the liver, where it may be used to address diseases of the liver itself or to transform the liver into a living “biofactory” for expressing systemic proteins to treat a wide variety of genetic diseases.
Our vision is to enable a new generation of people to live full lives unaffected by genetic disease.
We aim to make our therapies available at or near birth to maximize their lifetime impact. Patients diagnosed with a genetic disease would receive GeneWave therapy, titrated as needed to achieve therapeutic benefit. GeneWave could then be re-dosed throughout childhood and on through adulthood, if and when needed, to sustain effect.
We are working towards this vision by developing and expanding our platform technology, and by translating our science into novel medicines for patients with a broad spectrum of genetic diseases.
The Generation Bio Community
Our team is building a community of innovators who can translate our vision with determination, rigor, and a sense of humor.